Parnax Lab Ltd

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite achieving record quarterly net sales, the company’s profitability and margin metrics have deteriorated, prompting a downgrade in its Mojo Grade from Hold to Sell as of 25 March 2026.

Parnax Lab Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Parnax Lab Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹170.00 crores, reported net profit of ₹2.18 crores for Q4 FY26 (Mar'26 quarter), marking a concerning decline of 19.56% quarter-on-quarter and 25.34% year-on-year. Despite robust revenue growth, the company's profitability came under severe pressure due to margin compression and elevated other income dependency, raising questions about the sustainability of its operational performance.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a robust long-term return profile, recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of investor sentiment amid broader market dynamics.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair to an attractive valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Hold, signals a potential reappraisal of the stock’s price attractiveness amid improving fundamentals and relative sector comparisons.

Surging from a 52-week low of Rs 87.5 to a fresh peak of Rs 182, Parnax Lab Ltd has delivered an impressive 80.28% return over the past year, significantly outperforming the Sensex which declined by 3.93% during the same period. This milestone comes amid a backdrop of broad technical strength that has propelled the stock higher despite a weakening broader market.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 Mar 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change comes amid a strong rally in its stock price, which has outperformed the Sensex significantly over multiple time horizons. Investors and analysts are now reassessing the company’s price attractiveness in light of its current price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical averages and peer benchmarks.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the most recent insights into the company’s performance and outlook.

With a 71.43% gain over the past year, Parnax Lab Ltd has surged from Rs 85.60 to a fresh 52-week high of Rs 169 on 28 Apr 2026, showcasing a remarkable price momentum that outpaces the Sensex’s decline of 3.70% over the same period.

Parnax Lab Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. Despite this adjustment, the company’s stock has delivered robust returns over multiple time horizons, outperforming the Sensex significantly. This article analyses the recent valuation changes, compares key metrics with peers, and assesses the implications for investors.

Parnax Lab Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with the latest insights into its performance and outlook.

With a decisive surge to Rs 166 on 17 Apr 2026, Parnax Lab Ltd has reached a fresh 52-week high, marking a 55.29% gain over the past year and outpacing the Sensex’s modest decline of 0.59%. This rally is underpinned by a strong alignment of technical indicators and sustained price momentum, even as the broader market trades cautiously.

Surging past its previous peak, Parnax Lab Ltd touched a fresh 52-week high of Rs 148 on 16 Apr 2026, marking a significant milestone in its price momentum. This rally reflects a confluence of bullish technical indicators and a strong recovery from its 52-week low of Rs 85.6, underscoring the stock’s robust upward trajectory amid a mixed broader market backdrop.